biosimilars

Arizona passes pharmacy biosimilar lawArizona recently joined around 20 other states by passing a law allowing pharmacists to substitute certain interchangeable biosimilar drugs for brand name drugs.
The biosimilar balance: More options, lower costsThe fly in the ointment: CMS' current plan for HCPCS codes is a real buzz kill.
Predictions for the future of high-cost specialty drugsIMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.
Biosimilars pose problems for Medicare beneficiaries
Biosimilars pose problems for Medicare beneficiariesSurprisingly, Medicare beneficiaries are likely to pay much more for biosimilars than the referenced brand medication, according to a new report.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
Addressing rising pharma costs: A roundtable discussionAt the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.
AMCP Annual Meeting highlights specialty pharmaceutical challengesThe CEO of the Academy of Managed Care Pharmacy identifies key challenges and opportunities that will be discussed at the annual meeting.
Assessing the impact of biosimilars on cost, qualityA new report from IMS Institute for Healthcare Informatics finds that biosimilar acceptance will grow and drive change in the healthcare system.
Biosimilar approvals deemed “too slow”While FDA’s approval last week of infliximab-dyyb (Inflectra, Celltrion and Hospira), a biosimilar to Remicade (Janssen Biotech) for rheumatoid arthritis, Chron’s disease and other conditions is positive, FDA’s approval pace for biosimilars is too slow, according to a pharmacy benefit manager (PBM).
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?